Stockreport

Century Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates [Yahoo! Finance]

Century Therapeutics, Inc.  (IPSC) 
PDF – Overall response rate (ORR) of 83% observed at CNTY-101 Dose Level 3B alongside a favorable safety profile in patients with r/r B-cell lymphomas in Phase 1 ELiPSE-1 s [Read more]